Financings of the Fortnight Wants To Spin You Right 'Round, And Out
This article was originally published in The Pink Sheet Daily
Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.
You may also be interested in...
Biogen participates with Atlas Venture in a $17 million Series A financing for Ataxion, which will seek to advance preclinical ion channel modulators for hereditary ataxias.
The upbeat ex-Shire exec has moved on from his tumultuous break-up with the specialty pharma and is on day three in his new role as CEO of CNS start-up SAGE Therapeutics. He will focus on bringing CNS products forward for orphan indications.
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.